Table 1 Clinical summary of 12 patients... | American Society of Hematology

Table 1

Clinical summary of 12 patients with kinase domain mutations

Patient no.	Age, y	Sex	Imatinib		Dasatinib			Best response on DB	Duration of treatment, mo	Current status
Patient no.	Age, y	Sex	Duration of IM treatment, mo	Best responseon IM	KD mutation before DB	Clinical phase at the start of DB	Cytogenetic analysis prior to DB, Ph+ %	Best response on DB	Duration of treatment, mo	KD mutation after DB
1	51	M	43	PCyR	H396R	CP	100	MMR	13+	None	MMR
2	28	M	35	CHR	E453V	CP	91	MMR	23+	None	MMR
3	58	F	24	CCyR	F359V	CP	N/A	CCyR	7+	None	CCyR
4	43	F	24	CHR	H396R	BC	100	MMR	14+	None	MMR
5	53	M	39	CHR	L248V	AP	89	PCyR	25	L248V	CHR
6	37	M	35	PCyR	G250R	AP	100	CCyR	24+	G250R	CCyR
7	55	M	48	PCyR	M244V	CP	100	CCyR	22+	M244V	PCyR
8	50	F	48	CCyR	M244V	CP	100	PCyR	23	F317L	CHR
9	40	M	58	CHR	M351T	AP	100	CHR	24+	F317L	CHR
10	56	F	36	CCyR	H396R (M351T)*	CP	43	CCyR	7+	F317L	PCyR
11	52	F	48	PCyR	F311I	BC	100	CCyR	8	F311I	Deceased (BC)
										T315I
12	24	F	7	PCyR	Y253H	BC	100	CCyR	6	Y253H	Deceased (BC)
										T315I

Patient no.	Age, y	Sex	Imatinib		Dasatinib			Best response on DB	Duration of treatment, mo	Current status
Patient no.	Age, y	Sex	Duration of IM treatment, mo	Best responseon IM	KD mutation before DB	Clinical phase at the start of DB	Cytogenetic analysis prior to DB, Ph+ %	Best response on DB	Duration of treatment, mo	KD mutation after DB
1	51	M	43	PCyR	H396R	CP	100	MMR	13+	None	MMR
2	28	M	35	CHR	E453V	CP	91	MMR	23+	None	MMR
3	58	F	24	CCyR	F359V	CP	N/A	CCyR	7+	None	CCyR
4	43	F	24	CHR	H396R	BC	100	MMR	14+	None	MMR
5	53	M	39	CHR	L248V	AP	89	PCyR	25	L248V	CHR
6	37	M	35	PCyR	G250R	AP	100	CCyR	24+	G250R	CCyR
7	55	M	48	PCyR	M244V	CP	100	CCyR	22+	M244V	PCyR
8	50	F	48	CCyR	M244V	CP	100	PCyR	23	F317L	CHR
9	40	M	58	CHR	M351T	AP	100	CHR	24+	F317L	CHR
10	56	F	36	CCyR	H396R (M351T)*	CP	43	CCyR	7+	F317L	PCyR
11	52	F	48	PCyR	F311I	BC	100	CCyR	8	F311I	Deceased (BC)
										T315I
12	24	F	7	PCyR	Y253H	BC	100	CCyR	6	Y253H	Deceased (BC)
										T315I

CCyR indicates complete cytogenetic response; PCyR, partial cytogenetic response; MMR, major molecular response; Ph+, Philadelphia chromosome positive; IM, imatinib mesylate; DB, dasatinib; NA, not available; CP, chronic phase; AP, accelerated phase; and BC, blast crisis.

The M351T mutation became undetectable during IM therapy, and undetectable prior to DB therapy.

View Large

This Feature Is Available To Subscribers Only